For media enquiries, please contact firstname.lastname@example.org
Conyers advised Hony Capital Fund V, L.P. and New Good Management Limited on the US$495 million privatization of Simcere Pharmaceutical Group from the New York Stock Exchange (“NYSE”) by way of merger. Simcere is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China.
Conyers co-chair David Lamb and Associate Angie Chu, both based in Conyers’ Hong Kong office, acted in this matter. They worked alongside Cleary Gottlieb Steen & Hamilton LLP and Shearman & Sterling LLP.